New heart catheter aims to zap Hard-to-Treat AFib

NCT ID NCT06960252

Recruiting now Disease control Sponsor: Ting-Yung Chang Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new catheter called OPTRELL™ to map and treat persistent atrial fibrillation (AF), a type of irregular heartbeat that is harder to treat. The device helps doctors identify and target the specific areas in the heart causing the problem. The trial will enroll 80 people with persistent AF to see if this approach reduces the chance of the arrhythmia returning after ablation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OPTRELL™ Mapping Catheter (a device used to map the heart's electrical signals during ablation)
What this could lead to: If successful, this could improve the precision of ablation for persistent atrial fibrillation, potentially reducing the chance of the arrhythmia coming back.
What could go wrong: This is a small, early-stage study (80 participants) testing a new device. The approach may not work better than standard ablation, and there are always risks with heart procedures like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF)

Contacts and locations

Locations

Taipei Veterans General Hospital
RECRUITING

Taipei, Outside US, 112, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.